Several phase II and III clinical trials have been initiated to inhibit key immunological processes of adipose tissue inflammation in T2D patients, such as NF-κB signaling, IL-1β function, or arachidonic acid metabolism, with promising results [148]. Here, IL1B is linked to type 2 diabetes mellitus.